AmCad BioMed

medical devices

About

AmCad BioMed Corporation, established in 2008, is a leader in the field of ultrasound AI diagnostic assessments for various clinical indications. The company was the first to receive an FDA license for ultrasound CAD solution, and has been publicly traded on the Taiwan Stock Exchange since 2015. Its products and pipeline feature the FDA cleared, CE marked and clinically validated soultions including (1) AmCAD-UT for thyroid nodules analysis, (2) AmCAD-UO for obstructive sleep apnea (OSA) detection, (3) AmCAD-US for backscattered signals analysis useful in Liver Steatosis and other diagnosis capabilities, (4) AmCAD-CA for thyroid FNA cytopathology indication, (5) and the state-of-the-art LIVE ultrasound AI detection modules (need to be intragrated into an ultrasound platform) to make diagnosis in real-time for thyroid and breast indications.

Technologies

Gmail Google Apps Mobile Friendly YouTube Apache reCAPTCHA Google Tag Manager Reviews Remote

Keywords

thyroid cancer detection obstructive sleep apnea detection breast cancer detection ultrasound imaging detection deep learning medical ai liver steatosis ultrasound ai analysis compelement of ent dise accessment medical equipment manufacturing medical device software fda cleared ultrasound ai medical equipment and supplies manufacturing sleep disorder diagnostics fda 510(k) clearance thyroid nodule analysis sonographic analysis healthcare technology liver disease detection pioneering ultrasound ai ai cytopathology healthcare ai solutions b2b computer-assisted detection ultrasound image processing data analytics ultrasound guided intervention ai-powered ultrasound detection medical diagnostics automation ultrasound image analytics medical imaging

Location

167 復興北路, Taipei City, Taiwan, 105

Related Companies

Companies in the same industry